A new prostate cancer drug is bringing hope to many patients battling a common form of the disease. On March 28, Novartis announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of Pluvicto, a targeted radioligand therapy. This treatment is designed to be given before chemotherapy and aims to help those with a specific type of advanced prostate cancer.
Prostate cancer is a serious health issue, particularly for men. It is the second leading cause of cancer death among men, with metastatic castration-resistant prostate cancer (mCRPC) accounting for a significant number of these deaths. The new approval allows three times as many patients to access Pluvicto, which was first approved in March 2022.
Pluvicto works by targeting prostate cancer cells in the body. It is administered through an IV and attaches to these cells, either stopping them from growing or killing them outright. This approach is particularly beneficial for patients who have already undergone treatment with androgen receptor pathway inhibitors, which are commonly used for metastatic prostate cancer.
In clinical trials, Pluvicto demonstrated impressive results, significantly reducing the risk of disease progression or death by 59% among patients with mCRPC. Experts believe this expanded approval could change how doctors treat this aggressive form of cancer. Dr. Michael Morris, a leading researcher in the field, noted that this treatment offers a better option for patients who have not yet received chemotherapy.
The FDA’s decision reflects a growing interest in targeted therapies that can provide more effective treatment options. Novartis is committed to making Pluvicto available at nearly 600 treatment sites across the U.S.
While the drug shows promise, it does come with some side effects. Patients have reported experiencing dry mouth, fatigue, nausea, and constipation. However, many are hopeful that the benefits of Pluvicto will outweigh these challenges.
Looking ahead, Novartis plans to explore the use of radioligand therapies for other advanced cancers, including breast, colon, neuroendocrine, lung, and pancreatic cancers. This could pave the way for new treatments that improve outcomes for many more patients in the future.